A Phase 3 interventional study of Ofloxacin and Avelox (Moxifloxacin, BAY12-8039) in Pelvic Inflammatory Disease, sponsored by Bayer. Completed at 77 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease
37 studies on the registry are indexed under Pelvic Inflammatory Disease; 5 are open to participants now.
This study's enrollment of 749 is above the median of 163 across 30 interventional studies indexed under Pelvic Inflammatory Disease.
Browse Pelvic Inflammatory Disease studies →Bayer is the lead sponsor of 1,643 studies on the registry; 57 are open to participants now.
Of its 209 completed or terminated interventional studies of FDA-regulated products, 129 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Ofloxacin
Drug: Avelox (Moxifloxacin, BAY12-8039)
Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
Moxifloxacin 400 mg po od for 14 days
Clinical response 5 to 24 days after the last dose of study medication
Time frame: 5 to 24 days after the last dose
Bacterial response at the test of cure visit and at the FU visit 28 to 42 days after last dose of study medication
Time frame: visit 28 to 42 days after last dose
Clinical response at during-treatment visit (Day 4-7) and at follow-up 28 to 42 days after last dose
Time frame: (Day 4-7) and at follow-up 28 to 42 days after last dose
Reduction from baseline in pain report at the different assessment visits
Time frame: Over the entire trial period (overall)
Necessity for modifying antibiotic therapy at the during-treatment visit and TOC visit and necessity for institution of an antibiotic therapy at follow-up
Time frame: Over the entire trial period (overall)
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer